ERBB2 and neoplasm: Like lapatinib, AZD8931 is a dual inhibitor of both HER2 and HER1; however, it has a unique profile of activity, being a more effective inhibitor of HER family signalling than lapatinib, resulting in a distinct profile of anti-tumour activity (Hickinson et al., 2010).